The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
Two biopharmaceutical experts join SK bioscience to strengthen the future strategies
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.
The goal is to bring oncology therapy closer to the communities by integrating all services such as chemotherapy and radiation centers
The AGE1.CR.pIX cell line is derived from primary cells of a duck embryo and was designed to comply with health authority guidelines
The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
Subscribe To Our Newsletter & Stay Updated
